Myriad Genetics Hires Five Senior Executives to Advance Business Growth Plans

Myriad Genetics Hires Five Senior Executives to Advance Business Growth Plans

Myriad Genetics, Inc.

Myriad Genetics, Inc.

  • New leaders to elevate product portfolio, customer-centric business capabilities, and sales and marketing execution

SALT LAKE CITY, Dec. 19 10, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the arrival of five senior executives to help further strengthen the company product roadmap and improve business execution.

  • Marc Leighton recently joined Myriad as Senior Vice President (SVP) for Product Management. Leighton is responsible for leading product strategy across the organization. He has over 15 years of healthcare experience and has held various product leadership positions in global devices and software, most recently as Vice President of Products at Florence Healthcare.

  • Glenn Farrell recently joined Myriad as SVP and Chief Marketing Officer (CMO). Farrell is responsible for leading the company’s brand, digital marketing and communications strategy. He has over 25 years of experience leading successful brand strategies and go-to-market programs in healthcare, life sciences and technology. He most recently served as CMO and founding team member of Sema4 Holdings Corp.

  • Lisa Olson-Coombe recently joined Myriad as Vice President of Lab Transformation. Olson-Coombe is responsible for leading Myriad’s efforts to relocate and modernize core labs in Salt Lake City and south San Francisco. She has over 20 years of experience managing large-scale diagnostic laboratory operations, most recently as Vice President of Laboratory Operations at Exact Sciences Corp.

  • John Oberg will join Myriad as Senior Vice President of Business Development effective January 3, 2023. Oberg will be responsible for developing business partnerships and establishing collaborations with biotechnology companies, healthcare networks, health systems and academic partners. He has over 15 years of experience in healthcare, genomics and precision medicine, most recently as a business development manager at Invitae Corp.

  • Michael Lyons will join Myriad as Managing Director of Oncology effective January 3, 2023. Lyons will lead Oncology’s go-to-market strategy and oversee team members in Sales, Marketing, Medical Affairs and customer service. He has over 20 years of experience in the health field, with expertise in the field of oncology. He previously served as SVP for North America at Novocure Ltd.

“We are delighted to welcome Marc, Glenn, Lisa, John and Michael to the Myriad team. They are all accomplished leaders who will each be instrumental in accelerating the growth of our business and elevating our products to their full potential,” said Paul J. Diaz, President and Chief Executive Officer. by Myriad Genetics. “Their combined deep healthcare experience and respective areas of expertise will continue to enrich our strong foundation for long-term sustainable growth, profitability and innovation.”

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to promoting health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing a disease or its progression and guide treatment decisions in medical specialties where genetic information can significantly improve patient care and reduce healthcare costs. . Fast Company named Myriad among the The most innovative companies in the world for 2022. For more information, visit

Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, SneakPeek, Health.Illuminated., RiskScore , Prolaris, GeneSight and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved.

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to enhancements to the company’s product portfolio, customer-centric business capabilities and sales and marketing execution, to accelerating the company’s growth. business operations, the company’s strong foundation for long-term sustainable growth, profitability and innovation, and Oberg and Lyons joining the company effective January 3, 2023. These “forward-looking statements” are the expectations of the management regarding future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially and adversely from those anticipated. These factors include the risks described in the company’s filings with the United States Securities and Exchange Commission, including the company’s annual report on Form 10-K filed on February 25, 2022, as well as any updates of these risk factors filed from time to time in the company’s quarterly reports on Form 10-Q or current reports on Form 8-K.

Media Contact:
Glenn Farrel
(801) 505-5195

Investor contacts:
Matt Scalo
(801) 584-3532

#Myriad #Genetics #Hires #Senior #Executives #Advance #Business #Growth #Plans

Leave a Comment

Your email address will not be published. Required fields are marked *